Kazia Therapeutics – introducing novel asset EVT-801

Kazia Therapeutics – introducing novel asset EVT-801

Associated equity: Kazia Therapeutics

Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.

Kazia Therapeutics — 9 videos in collection

Kazia Therapeutics is an oncology focused drug development company based in Sydney, Australia. In addition to Kazia’s lead programme, paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway developed to treat the most common form of brain cancer, the company is developing EVT-801, a small molecule inhibitor of VEGFR3. Preclinical data have shown EVT-801 to be active against a broad range of tumor types.

In this video, Dr James Garner, CEO of Kazia, discusses the rationale behind acquiring the asset, the company’s plans for a Phase I trial and what investors can expect over the next year.

You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free